TIBCS 2025 Channel(2) : When immunotherapy meets ADCs — a new frontier emerges in triple-negative breast cancer treatment.”

In this episode of TIBCS 2025 Channel, Professor Sherene Loi (Peter MacCallum Cancer Centre, Australia) and Professor Sung-bae Kim (Yonsei University College of Medicine, Korea) share their expert insights on the evolving treatment landscape of triple-negative breast cancer (TNBC).

Hosted by Dr. Chia-Yen Hung (Mackay Memorial Hospital, Taiwan) and Dr. Ching-Tso Chen (National Taiwan University Hsin-Chu Branch), the discussion explores current first-line management and its limitations, the rationale for combining antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs), and the clinical implications of pivotal trials such as ASCENT-04 and KEYNOTE-D19.

The professors also discuss unique immune response characteristics in Asian patients, personalized treatment considerations, and the future directions shaping the next era of TNBC care.